Shanghai RAAS Blood Products Co., Ltd. logo

Shanghai RAAS Blood Products Co., Ltd. (002252)

Market Closed
12 Dec, 06:57
XSHE XSHE
¥
6. 44
+0.01
+0.16%
¥
44.01B Market Cap
26.52 P/E Ratio
0.13% Div Yield
33,860,835 Volume
0.36 Eps
¥ 6.43
Previous Close
Day Range
6.4 6.6
Year Range
6.4 7.77
Want to track 002252 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

002252 closed today higher at ¥6.44, an increase of 0.16% from yesterday's close, completing a monthly decrease of -2.42% or ¥0.16. Over the past 12 months, 002252 stock lost -10.8%.
002252 pays dividends to its shareholders, with the most recent payment made on Jul 14, 2025. The next estimated payment will be in In 1 month on Jan 14, 2026 for a total of ¥0.033.
The last earnings report, released on Oct 28, 2025, missed the consensus estimates by -0.02%. On average, the company has fell short of earnings expectations by -0.02%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on XSHE (CNY).

002252 Chart

Similar

Aier Eye Hospital Group Co. Ltd.
¥ 11.11
+0.91%
Haisco Pharmaceutical Group Co., Ltd.
¥ 55.42
-1.74%
Shannon Semiconductor Tech Inc.
¥ 141.99
-0.82%
Sichuan Kelun Pharmaceutical Co., Ltd.
¥ 31.12
-2.72%
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
¥ 68.22
-0.15%

Shanghai RAAS Blood Products Co., Ltd. (002252) FAQ

What is the stock price today?

The current price is ¥6.44.

On which exchange is it traded?

Shanghai RAAS Blood Products Co., Ltd. is listed on XSHE.

What is its stock symbol?

The ticker symbol is 002252.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0.13%.

What is its market cap?

As of today, the market cap is 44.01B.

Has Shanghai RAAS Blood Products Co., Ltd. ever had a stock split?

No, there has never been a stock split.

Shanghai RAAS Blood Products Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
Mr. Jun Xu CEO
XSHE Exchange
CNE100000C31 ISIN
CN Country
3,350 Employees
- Last Dividend
28 Sep 2016 Last Split
23 Jun 2008 IPO Date

Overview

Shanghai RAAS Blood Products Co., Ltd. is a prominent company based in Shanghai, China, specializing in the development, manufacturing, and sale of various blood products. Established in 1988, the company has grown to become one of China's leading suppliers in the blood product industry. Through its extensive research and development efforts, Shanghai RAAS has been able to offer a wide range of critical blood-derived products that are essential in the medical treatment of various diseases and conditions.

Products and Services

Shanghai RAAS Blood Products Co., Ltd. provides an expansive portfolio of blood products, catering to different medical needs. These include:

  • Human Serum Albumin: Utilized commonly in the treatment of shock, burns, and other conditions requiring plasma volume replacement.
  • Human Intravenous Immunoglobulin: Offers vital immune support for individuals with immune deficiencies and is used in the treatment of various autoimmune and inflammatory diseases.
  • Human Coagulation Factor VIII: Essential for the management and treatment of hemophilia A, a genetic disorder impairing blood coagulation.
  • Human Prothrombin Complex: Used in the management of bleeding disorders, especially for patients with deficiencies in clotting factors.
  • Human Fibrinogen: A critical factor in blood clot formation, used in the treatment of congenital and acquired fibrinogen deficiency.
  • Human Thrombin and Human Fibrin Adhesive: These products are used in surgeries as hemostatic agents to control bleeding.
  • Human Immunoglobulin: Plays a role in boosting the immune system, especially for patients with weakened immune systems.
  • Hepatitis B Immunoglobulin: Provides passive immunity to hepatitis B, used particularly after exposure to the virus or for newborns of infected mothers.
  • Tetanus Immunoglobulin: Offers passive immunization against tetanus in cases of wounds likely to be contaminated with Clostridium tetani.
  • Rabies Immunoglobulin: Provides immediate protection against the rabies virus following exposure before the vaccine starts to take effect.

Contact Information

Address: No. 2009, Wangyuan Road, Shanghai, China, 201401
Phone: 86 21 2213 0888